Mersana Therapeutics Inc. (MRSN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Mersana Therapeutics Inc.

    NASDAQ: MRSN · Real-Time Price · USD
    7.23
    0.06 (0.84%)
    At close: Sep 26, 2025, 1:14 PM

    Mersana Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 40.5M 36.85M 26.58M 43K
    Cost of Revenue
    		 1.63M 148.27M 927K 132.01M
    Gross Profit
    		 38.87M -111.41M 25.65M -131.97M
    Operating Income
    		 -73.34M -170.96M -204.69M -169.71M
    Interest Income
    		 8.44M 12.07M 2.88M 65K
    Pretax Income
    		 -68.77M -171.67M -204.21M -170.06M
    Net Income
    		 -69.19M -171.67M -207.54M -169.21M
    Selling & General & Admin
    		 40.81M 59.54M 56.96M 36.89M
    Research & Development
    		 73.02M 148.27M 173.38M 132.01M
    Other Expenses
    		 n/a n/a -445K -1.2M
    Operating Expenses
    		 113.83M 36.85M 230.35M 168.9M
    Interest Expense
    		 3.87M 4.07M 3.33M 1.27M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 113.83M 207.81M 230.35M 168.9M
    Income Tax Expense
    		 418K n/a 3.33M -855K
    Shares Outstanding (Basic)
    		 4.9M 4.64M 3.75M 2.82M
    Shares Outstanding (Diluted)
    		 4.9M 4.64M 3.75M 2.82M
    EPS (Basic)
    		 -14.12 -36.96 -54.51 -60.24
    EPS (Diluted)
    		 -14.12 -36.96 -54.51 -60.24
    EBITDA
    		 -63.27M -166.08M -199.96M -167.94M
    EBIT
    		 -64.9M -167.6M -200.88M -168.79M
    Depreciation & Amortization
    		 1.63M 1.52M 927K 855K

    Add to Watchlist